Researchers reported today that patients treated with CellCept® (mycophenolate mofetil), a drug used to prevent rejection in organ transplantation, have significantly lower progression of intimal ...

A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis. A ...

Mycophenolate mofetil (CellCept) was as effective as cyclophosphamide for remission induction in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, Japanese researchers reported. In a ...

July 24, 2006 -- Malaysia's Drug Control Authority has approved a new indication for mycophenolate mofetil, allowing its use in conjunction with corticosteroid therapy for the induction and ...

June 9, 2006 — The U.S. Food and Drug Administration (FDA) has approved orphan drug status for mycophenolate mofetil in the treatment of pemphigus vulgaris; second-generation antisense drug for the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted a prior approval supplement to Zydus Lifesciences Limited allowing the company to market its ...

TORONTO, June 4 /PRNewswire/ -- The 12-month results from a multicenter trial monitoring CellCept(R) (mycophenolate mofetil) in combination with calcineurin inhibitors (CNIs) in renal transplantation ...

Lannett is offering mycophenolate mofetil for oral suspension, 200 mg/mL, an internally developed product. The medication is the generic of Roche Palo Alto’s CellCept. It is indicated for the ...

The FDA has issued an alert regarding the increased risk of first trimester spontaneous abortion and fetal congenital malformations with the use of CellCept (mycophenolate mofetil, from Roche) and ...

PHILADELPHIA, Aug. 30, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL, an internally ...

CHAPEL HILL, N.C. – A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for ...